Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 36,157

Document Document Title
WO/2018/070824A1
Disclosed are a compound represented by chemical formula 1; an organic electric element including a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode; and an electroni...  
WO/2018/069732A1
This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compo...  
WO/2018/070836A1
An organic electronic device and an electronic apparatus comprising same are disclosed. The organic electronic device comprises: a compound represented by chemical formula (1); a first electrode; a second electrode; and an organic layer ...  
WO/2018/069490A1
A compound of formula (I) : (I) and its conjugates.  
WO/2018/070773A1
The present disclosure relates to an organic electroluminescent device. The organic electroluminescent device of the present disclosure can provide a low driving voltage and excellent luminous efficiency by comprising a specific combinat...  
WO/2018/071836A1
Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria...  
WO/2018/068759A1
The present invention relates to a five-membered heteroaryl ring bridged ring derivative, a preparation method therefor and the medical use thereof. In particular, the present invention relates to a new five-membered heteroaryl ring brid...  
WO/2018/071794A1
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.  
WO/2018/069222A1
The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compoun...  
WO/2018/067551A1
The present disclosure relates to texaphyrin compounds linked with an antitumor antibiotic such as an anthcyanine antitumor antibiotic such as doxorubicin and danurubicin. The texaphyrin and the antitumor antibiotic are joined together b...  
WO/2018/068017A1
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R", Q, W, X, Y, Z, n1...  
WO/2018/067432A1
Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of formula I are us...  
WO/2018/066812A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure can provide an organic electrolumine...  
WO/2018/067512A1
Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.  
WO/2018/065365A1
The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I), wherein the variables have the meaning defined in the claims. The compounds according to the present i...  
WO/2018/067659A1
Despite its power in identifying highly potent ligands for select protein targets, conventional medicinal chemistry is limited by its low throughput and lack of proteomic selectivity information. We seek to develop a chemoproteomic appro...  
WO/2018/064735A1
The present invention patent application relates to a novel process for producing carboxy metallo-phthalocyanines that can be used for producing dyes and pigments for the textile industry, inter alia, which is more efficient in producing...  
WO/2018/065340A1
The present invention relates to a compound of formula (I), wherein R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy or lower alkoxy substituted by halogen; and R1 may be different if n is 2 or 3; R2...  
WO/2018/064797A1
A crystal form of ACP-196, a preparation method of the crystal form, a pharmaceutical composition thereof and use of the crystal form in the preparation of drugs for treatment and/or prevention of Bruton's tyrosine kinase (BTK)-mediated ...  
WO/2018/067615A1
The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are i...  
WO/2018/066718A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : in which n, X, R1, R2, R3 and R4 are as defined in the specification, processes for their preparation, pharmaceutical compositions co...  
WO/2018/062758A1
The present disclosure relates to an organic electroluminescent material comprising at least two types of compounds and an organic electroluminescent device comprising the same. The organic electroluminescent device having better color p...  
WO/2018/064510A1
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I), or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein B, W, X, Y, R1, R...  
WO/2018/062543A1
[Problem] When tryptanthrin is extracted from indigo leaves with ethanol, chlorophyll is eluted from the indigo leaves and therefore a tryptanthrin-containing indigo leaf extract is discolored into a blackish green color. [Solution] Indi...  
WO/2018/060742A1
The present invention relates to a class of substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30)...  
WO/2018/060367A1
The present invention relates to compounds according to general formula (1) for use in the treatment of a bacterial infection, particularly for use in the treatment of a bacterial infection with methicillin resistant Staphylococcus aureu...  
WO/2018/062778A1
The present disclosure relates to an organic electroluminescent device comprising a first electrode, a second electrode facing the first electrode, a light-emitting layer between the first electrode and the second electrode, and an elect...  
WO/2018/064135A1
The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these c...  
WO/2018/062732A1
The present invention relates to a novel pyridine derive compound or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition using same.  
WO/2018/064557A1
The present disclosure relates to substituted fused bi- or tri- heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell a...  
WO/2018/064080A1
Compounds disclosed herein including compounds of Formula I: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for ...  
WO/2018/059216A1
Disclosed are compounds reducing SAICAR synthase activity, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain c...  
WO/2018/061446A1
Provided is an organic electroluminescent (organic EL) element having high efficiency while having low drive voltage, and having high drive stability. In a luminous layer formed between an opposing anode and cathode, the organic electrol...  
WO/2018/060354A1
The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them, wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and ot...  
WO/2018/061045A1
Calixpyrrole-based antitumor compounds are described, which can be derivatized to obtain their passive transport on tumor masses through the Enhanced Permeation and Retention, EPR, effect of the neoplastic vasculature. The conjugation of...  
WO/2018/059437A1
Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R) -2-fluoro-10a-methyl-7, 8, 9, 10, 10a,...  
WO/2018/055402A1
The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined her...  
WO/2018/057810A1
The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, n, R1, R2, R3, R4, R5, and R6 are as described herein. The compounds of formula I se...  
WO/2018/058091A1
Described herein are divalent nucleobases that each binds two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone, such as in a γ-peptide nucleic acid (γPNA). Also provided ...  
WO/2018/057884A1
The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further rel...  
WO/2018/054989A1
The invention relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kin...  
WO/2018/057973A1
Disclosed are compounds of Formula I (a) or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, R5, R6, R7, G1, G2 and Ring A are as described in any of the embodiments describ...  
WO/2018/055040A1
There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof) (I) that inhibit phosphatidylinositol 3-kinase gamma (PI3Kδ) and phosphatidylinositol 3-kinase gamma (ΡΙ3Κγ) activity, to their utilit...  
WO/2018/053643A1
Described herein are compositions and methods for modulating cellular senescence of a cell or induction of the senescence-associated secretory phenotype (SASP) in a cell. The methods generally comprise modulating the level or activity of...  
WO/2018/056855A1
This invention relates to: (a) compounds of Formula Ia (with R1, R4, R5, R6, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-β-hydroxylase inhibitors; (b) pharmaceutical c...  
WO/2018/055097A1
The present invention relates to LIM Kinase inhibitors of Formula (I) and pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4, X1, X2, X3, Y1, Y2 and Z are as defined in the claims, and their use for the treatme...  
WO/2018/052058A1
The present invention provides: a heterocyclic compound which has an IRAK-4-inhibiting activity and is expected to be useful for the prevention/treatment of inflammatory diseases, autoimmune diseases, osteoarticular degenerative diseases...  
WO/2018/053267A1
The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the me...  
WO/2018/050584A1
The invention relates to spirobifluorene derivatives which are substituted with electrone transport groups, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to t...  
WO/2018/052772A1
The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these comp...  

Matches 1 - 50 out of 36,157